Loading the section…

UTMD: financial statements from SEC — TradeAlmanac

UTMD

Utah Medical Products, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Revenue	9M	9M	10M	10M	10M	9M	10M	10M
Cost of revenue	3M	—	4M	4M	4M	—	4M	4M
Gross profit	5M	5M	6M	6M	6M	5M	6M	6M
Research and development	154,000	—	167,000	135,000	154,000	—	172,000	255,000
Selling, general and administrative	3M	—	3M	2M	2M	—	2M	3M
Operating expenses	3M	—	3M	2M	2M	—	2M	3M
Operating income	3M	—	3M	3M	3M	—	3M	3M
Pre-tax income	3M	—	3M	4M	4M	—	4M	4M
Income tax	578,000	—	678,000	788,000	817,000	—	616,000	758,000
Net income	3M	3M	3M	3M	3M	3M	4M	3M
Earnings per share	0.82	—	0.82	0.94	0.92	—	1.02	0.98
Earnings per share, diluted	0.82	0.80	0.82	0.94	0.92	0.86	1.03	0.98
Weighted average shares	3M	—	3M	3M	3M	—	3M	4M
Weighted average shares, diluted	3M	—	3M	3M	3M	—	3M	4M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	87M	86M	84M	82M	83M	83M	88M	89M
Receivables	4M	4M	4M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	3M	4M
Depreciation and amortisation	211,000	200,000
Share-based compensation	120,000	82,000
Capital expenditure	130,000	184,000
Investing cash flow	−130,000	−184,000
Dividends paid	989,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator